← All drugs Report issue

egf816

Small moleculeexperimental

Clinical trial activity

7 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

5

Phase 2

4

Phase 3

0

Phase 4

0

Earliest trial started Jun 6, 2014 (NCT02108964)

Timeline

2010s

Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Jan 1, 2015
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Epidermal growth factor receptor erbB1INHIBITOR
EGFR inhibitor
EGF816 is an irreversible TKI that demonstrates selectivity for mutant EGFRs compared with WT EGFR and targets activating and resistance mutations with equal potency (doi: 10.1158/1538-7445.AM2014-1734).
- Epidermal growth factor receptor (EGFR) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3545234 ↗

Also known as

egf816
egf816
egf816
egf-816
egf-816

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03516214	Phase 1	Apr 25, 2018	University of Cologne
NCT03333343	Phase 1	Jan 29, 2018	Novartis
NCT03292133	Phase 2	Oct 31, 2017	Harvard University, Novartis
NCT02900664	Phase 1	Aug 23, 2016	Novartis
NCT02323126	Phase 2	Feb 9, 2015	Novartis
NCT02335944	Phase 1/Phase 2 (Phase 2)	Jan 13, 2015	Novartis
NCT02108964	Phase 1/Phase 2 (Phase 2)	Jun 6, 2014	Novartis

Showing 7 of 7 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Novartis	For profit	6	5	2	2014
Harvard University	Academic/Hospital	1	1	1	2017
University of Cologne	Academic/Hospital	1	1	1	2018

3 organizations

Page 1 / 1